Read by QxMD icon Read


Monica Centa, Hong Jin, Lisa Hofste, Sanna Hellberg, Albert Busch, Roland Baumgartner, Nienke J Verzaal, Sara Lind Enoksson, Ljubica Perisic Matic, Sanjay V Boddul, Dorothee Atzler, Daniel Y Li, Changyan Sun, Göran K Hansson, Daniel F J Ketelhuth, Ulf Hedin, Fredrik Wermeling, Esther Lutgens, Christoph J Binder, Lars Maegdefessel, Stephen G Malin
BACKGROUND: Atherosclerosis progression is modulated by interactions with the adaptive immune system. Humoral immunity can help protect against atherosclerosis formation, however the existence, origin and function of putative atherogenic-antibodies is controversial. How such atherosclerosis-promoting antibodies could affect the specific composition and stability of plaques, as well as the vasculature generally, remains unknown. METHODS: We addressed the overall contribution of antibodies to atherosclerosis plaque formation, composition and stability in vivo with mice that 1) displayed a general loss of antibodies, 2) that had selectively ablated germinal center-derived IgG production or 3) through interruption of T-B cell interactions, and further studied the effects of antibody deficiency on the aorta by transcriptomics...
March 21, 2019: Circulation
Glenn N Levine, Patrick T O'Gara, Joshua A Beckman, Sana M Al-Khatib, Kim K Birtcher, Joaquin E Cigarroa, Lisa de Las Fuentes, Anita Deswal, Lee A Fleisher, Federico Gentile, Zachary D Goldberger, Mark A Hlatky, José A Joglar, Mariann R Piano, Duminda N Wijeysundera
No abstract text is available yet for this article.
March 20, 2019: Circulation
Roni Nielsen, Niels Møller, Lars C Gormsen, Lars Poulsen Tolbod, Nils Henrik Hansson, Jens Sorensen, Hendrik Johannes Harms, Jørgen Frøkiær, Hans Eiskjaer, Nichlas Riise Jespersen, Søren Mellemkjaer, Thomas Ravn Lassen, Kasper Pryds, Hans Erik Bøtker, Henrik Wiggers
BACKGROUND: Myocardial utilization of 3-hydroxybutyrate (3-OHB) is increased in patients with heart failure and reduced ejection fraction (HFrEF). However, the cardiovascular effects of increased circulating P-3-OHB levels in these patients are unknown. Consequently, our aim was to modulate circulating 3-OHB levels in HFrEF patients and evaluate: 1) changes in cardiac output (CO), 2) a potential dose-response relationship between 3-OHB levels and CO, 3) the impact on myocardial external energy efficiency (MEE) and oxygen consumption (MVO2 ), and 4) whether the cardiovascular response differed between HFrEF patients and age-matched volunteers...
March 19, 2019: Circulation
Janice Bonsu, Lawrence Charles, Avirup Guha, Farrukh Awan, Jennifer Woyach, Vedat Yildiz, Lai Wei, Hani Jneid, Daniel Addison
Cardiovascular disease (CVD) is increasingly common among new cancer patients, with a reported prevalence near 30% at diagnosis.1,2 Cancer patients with concurrent CVD have poorer outcomes than those without CVD.1-3 Despite the high prevalence of CVD and its prognostic significance, there is limited evidence to guide the care of this increasing population. One possible explanation may be the exclusion of CVD patients from clinical trials.3 In the US, pivotal clinical trials of anticancer drugs are reviewed by the Food and Drug Administration (FDA) for adequate representation and safety prior to approval and release...
March 18, 2019: Circulation
Remo H M Furtado, Marc P Bonaca, Itamar Raz, Thomas A Zelniker, Ofri Mosenzon, Avivit Cahn, Julia Kuder, Sabina A Murphy, Deepak L Bhatt, Lawrence A Leiter, Darren K McGuire, John P H Wilding, Christian T Ruff, Jose C Nicolau, Ingrid A M Gause-Nilsson, Martin Fredriksson, Anna Maria Langkilde, Marc S Sabatine, Stephen D Wiviott
BACKGROUND: Sodium glucose transporter-2 inhibitors (SGLT2i) reduce the risk of major adverse cardiovascular events (MACE) in patients with type 2 diabetes mellitus (T2DM) and a history of atherosclerotic cardiovascular (CV) disease (ASCVD). Because of their baseline risk, patients with prior myocardial infarction (MI) may derive even greater benefit from SGLT2i therapy. METHODS: DECLARE TIMI-58 randomized 17,160 patients with T2DM and either established ASCVD (n = 6,974) or multiple risk factors (MRF) (n = 10,186) to dapagliflozin versus placebo...
March 18, 2019: Circulation
Eri T Kato, Michael G Silverman, Ofri Mosenzon, Thomas A Zelniker, Avivit Cahn, Remo H M Furtado, Julia Kuder, Sabina A Murphy, Deepak L Bhatt, Lawrence A Leiter, Darren K McGuire, John P H Wilding, Marc P Bonaca, Christian T Ruff, Akshay S Desai, Shinya Goto, Peter A Johansson, Ingrid Gause-Nilsson, Per Johanson, Anna Maria Langkilde, Itamar Raz, Marc S Sabatine, Stephen D Wiviott
BACKGROUND: In DECLARE-TIMI 58, the sodium glucose co-transporter 2 inhibitor (SGLT2i) dapagliflozin reduced the composite endpoint of cardiovascular (CV) death/ hospitalization for heart failure (HHF) in a broad population of patients with T2DM. However, the impact of baseline left ventricular ejection fraction (EF) on the clinical benefit of SGLT2i is unknown. METHODS: In the DECLARE-TIMI 58 trial, baseline HF status was collected from all patients and EF where available...
March 18, 2019: Circulation
Subodh Verma, John J V McMurray
Diabetes intersects with cardiovascular disease at every level. While there has been much focus on understanding atherosclerotic complications, less well appreciated is the relationship between diabetes and heart failure. In addition to being a key and independent risk factor for the development of heart failure,1 diabetes is also one of the most important adverse prognostic factors in those with established heart failure with either reduced or preserved ejection fraction. 1,2 Diabetes is associated with a high prevalence of unrecognized left ventricular diastolic and systolic dysfunction, and accelerates the development of overt heart failure compared to similar patients without diabetes...
March 18, 2019: Circulation
Vasanti S Malik, Yanping Li, An Pan, Lawrence De Koning, Eva Schernhammer, Walter C Willett, Frank B Hu
No abstract text is available yet for this article.
March 18, 2019: Circulation
J Wouter Jukema, Rohit J Timal, Joris I Rotmans, Liselotte C R Hensen, Maurits S Buiten, Mihaly K de Bie, Hein Putter, Aeilko H Zwinderman, Lieselot van Erven, M Jacqueline Krol-van Straaten, Nienke Hommes, Bas Gabreëls, Wim van Dorp, Bastiaan van Dam, Charles A Herzog, Martin J Schalij, Ton J Rabelink
BACKGROUND: End-stage renal disease patients on dialysis are reported to be at high risk of sudden cardiac death (SCD) and, to date, no therapy has been shown to be effective in reducing this. The feasibility and value of prophylactic implantable cardioverter-defibrillator (ICD) implantation to prevent SCD is uncertain. METHODS: We conducted the ICD2 trial, a prospective, randomized controlled study investigating the value and safety of ICD implantation to prevent SCD in 200 patients on dialysis with a left ventricular ejection fraction ≥35%, after adequate screening and optimization of other treatments...
March 18, 2019: Circulation
Gemma A Figtree, Karin Rådholm, Terrance D Barrett, Vlado Perkovic, Kenneth W Mahaffey, Dick de Zeeuw, Greg Fulcher, David R Matthews, Wayne Shaw, Bruce Neal
Patients with type 2 diabetes mellitus are at high risk of developing heart failure (HF).1 Sodium glucose co-transporter 2 (SGLT2) inhibitors have been demonstrated, in large scale trials, to reduce the risk of HF events in patients with type 2 diabetes deemed to be at high risk based on established cardiovascular disease or multiple risk factors.2-4 However, it is unclear whether benefits are experienced across the broad spectrum of HF patients that includes those with preserved (HFpEF) as well as reduced ejection fraction (HFrEF)...
March 17, 2019: Circulation
Michel Azizi, Roland E Schmieder, Felix Mahfoud, Michael Weber, Joost Daemen, Melvin D Lobo, Andrew S P Sharp, Michael J Bloch, Jan N Basile, Yale Wang, Manish Saxena, Philipp Lurz, Florian Rader, Jeremy William Sayer, Naomi Deirdre Lakshmi Fisher, David Fouassier, Neil C Barman, Helen Reeve-Stoffer, Candace McClure, Ajay J Kirtane
BACKGROUND: The multicenter, international, randomized, blinded, sham-controlled RADIANCE-HTN SOLO trial demonstrated a 6.3 mmHg greater reduction in daytime ambulatory systolic blood pressure (BP) at 2 months by endovascular ultrasound renal denervation (RDN) compared with a sham procedure among patients not treated with antihypertensive medications. We report 6-month results following the addition of a recommended standardized stepped-care antihypertensive treatment (SSAHT) to the randomized endovascular procedure under continued blinding to initial treatment...
March 17, 2019: Circulation
Bart A Mulder, Isabelle C van Gelder, Michiel Rienstra
Stroke is a devastating complication of atrial fibrillation (AF) the odds of which can be reduced by use of oral anticoagulation based on the stroke risk score.1,2 Patients with asymptomatic clinical AF have a similar stroke risk as patients with symptomatic clinical AF.3 Thus far, electrocardiographic- (ECG) or Holter monitor-detected AF is a prerequisite before use of oral anticoagulation,1,2 because the guideline recommendations are based on studies that included only ECG- or Holter-detected AF ('clinical' AF)...
March 17, 2019: Circulation
Alexander C Perino, Jun Fan, Mariam Askari, Paul A Heidenreich, Edmund Keung, Merritt H Raitt, Jonathan P Piccini, Paul D Ziegler, Mintu P Turakhia
BACKGROUND: Device-detected atrial fibrillation (AF) is associated with increased risk of stroke. However, there are no clearly-defined thresholds of AF burden for which to initiate oral anticoagulation (OAC). We sought to describe OAC prescription practice variation in response to new device-detected AF and the association to outcomes. METHODS: We performed a retrospective cohort study using data from the Veterans Health Administration linked to remote monitoring data that included day-level AF burden...
March 17, 2019: Circulation
Donna K Arnett, Roger S Blumenthal, Michelle A Albert, Andrew B Buroker, Zachary D Goldberger, Ellen J Hahn, Cheryl D Himmelfarb, Amit Khera, Donald Lloyd-Jones, J William McEvoy, Erin D Michos, Michael D Miedema, Daniel Muñoz, Sidney C Smith, Salim S Virani, Kim A Williams, Joseph Yeboah, Boback Ziaeian
No abstract text is available yet for this article.
March 17, 2019: Circulation
Donna K Arnett, Roger S Blumenthal, Michelle A Albert, Andrew B Buroker, Zachary D Goldberger, Ellen J Hahn, Cheryl D Himmelfarb, Amit Khera, Donald Lloyd-Jones, J William McEvoy, Erin D Michos, Michael D Miedema, Daniel Muñoz, Sidney C Smith, Salim S Virani, Kim A Williams, Joseph Yeboah, Boback Ziaeian
No abstract text is available yet for this article.
March 17, 2019: Circulation
Vera A Bittner
Much of the cardiovascular disease burden and mortality can be traced back to four adverse health behaviors (smoking, poor diet, elevated body mass index, sedentary lifestyle) and three major risk factors (hypercholesterolemia, hypertension, diabetes). Ideal cardiovascular health defined as having all seven factors at goal is very rare among US adults. It is estimated that 87% of middle-aged US adults and 95% of individuals ≥60 years old meet ≤4 of these health metrics.1 Detailed guidelines are available that discuss cardiovascular risk assessment, lifestyle management, and treatment of individual risk factors...
March 17, 2019: Circulation
Tomoya Kitani, Sang-Ging Ong, Chi Keung Lam, June-Wha Rhee, Joe Z Zhang, Angelos Oikonomopoulos, Ning Ma, Lei Tian, Jaecheol Lee, Melinda L Telli, Ronald M Witteles, Arun Sharma, Nazish Sayed, Joseph C Wu
BACKGROUND: Molecular targeted chemotherapies have been shown to significantly improve cancer patient outcomes, but often cause cardiovascular side effects that limit their use and impair patients' quality of life. Cardiac dysfunction induced by these therapies, especially trastuzumab, shows a distinct cardiotoxic clinical phenotype compared to cardiotoxicity induced by conventional chemotherapies. METHODS: We employed the human induced pluripotent stem cell-derived cardiomyocyte (iPSC-CM) platform to determine the underlying cellular mechanisms in trastuzumab-induced cardiac dysfunction...
March 14, 2019: Circulation
Aruni Bhatnagar, Laurie P Whitsel, Michael J Blaha, Mark D Huffman, Suchitra Krishan-Sarin, John Maa, Nancy Rigotti, Rose Marie Robertson, John J Warner
The advent of new tobacco products such as electronic cigarettes and the dramatic rise in their use, especially by adolescents and young adults, are significant public health concerns. Electronic cigarettes have become the most popular tobacco products for youth and adolescents in the United States and are attracting youth to new avenues for nicotine addiction. Although these products may have benefit by helping some smokers quit or to move to a less harmful product, the long-term health effects of these products and the net public health effect associated with their use remain unclear and widely debated...
March 13, 2019: Circulation
Janani Rangaswami, Vivek Bhalla, John E A Blair, Tara I Chang, Salvatore Costa, Krista L Lentine, Edgar V Lerma, Kenechukwu Mezue, Mark Molitch, Wilfried Mullens, Claudio Ronco, W H Wilson Tang, Peter A McCullough
Cardiorenal syndrome encompasses a spectrum of disorders involving both the heart and kidneys in which acute or chronic dysfunction in 1 organ may induce acute or chronic dysfunction in the other organ. It represents the confluence of heart-kidney interactions across several interfaces. These include the hemodynamic cross-talk between the failing heart and the response of the kidneys and vice versa, as well as alterations in neurohormonal markers and inflammatory molecular signatures characteristic of its clinical phenotypes...
March 11, 2019: Circulation
Aruni Bhatnagar, Wasim Maziak, Thomas Eissenberg, Kenneth D Ward, George Thurston, Brian A King, Erin L Sutfin, Caroline O Cobb, Merlyn Griffiths, Larry B Goldstein, Mary Rezk-Hanna
Tobacco smoking with a water pipe or hookah is increasing globally. There are millions of water pipe tobacco smokers worldwide, and in the United States, water pipe use is more common among youth and young adults than among adults. The spread of water pipe tobacco smoking has been abetted by the marketing of flavored tobacco, a social media environment that promotes water pipe smoking, and misperceptions about the addictive potential and potential adverse health effects of this form of tobacco use. There is growing evidence that water pipe tobacco smoking affects heart rate, blood pressure regulation, baroreflex sensitivity, tissue oxygenation, and vascular function over the short term...
March 8, 2019: Circulation
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"